targeting the krad g12d mutation. mirati therapeutics has stated it was seeking investigational new drug (ind) approval in h1:2021 to start clinical trials. as of 2022 revolution medicines was exploring a small molecule therapy and reported anti-tumor activity in kras-g12d mutant tumor models. in 2021, the first clinical trial of a gene therapy targeting kras g12d was recruiting patients, sponsored by the national cancer institute. in june 2022, a case report was published about a 71-year-old woman with metastatic pancreatic cancer after extensive treatment (whipple surgery, radiation and multiple agent chemotherapy) who received a single infusion of her blood with engineered t cells with 2 genes encoding t cell receptors, directed to both the g12d mutation and an hla allele (hla-c*08:02). her tumor regressed persistently. but another similarly treated patient died from the cancer. interactions kras has been shown to interact with: c-raf, pik3cg, ralgds, and rassf2. calmodulin